NIDDK Central Repository, United States

Registration Status: Pending

Objective: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is part of the United States National Institutes of Health, which in turn is part of the Department of Health and Human Services. The NIDDK Central Repository (NIDDK-CR) is a contract-supported centralized repository managed by two separate yet integrated components: the Data Repository and the Biorepository. These components work together to acquire, store, and distribute resources generated from large multicenter studies supported by NIDDK or that are within the research areas and mission of NIDDK. The mission of the NIDDK-CR is to facilitate sharing of resources for secondary uses, thus encouraging work by junior or established investigators, investigators with novel approaches, and others not included in current collaborations. Secondary research use helps to maximize research participants’ contributions and decreases duplicative sampling efforts, thereby increasing the scientific value and impact of the originating study. Established in 2003, the NIDDK-CR has continually expanded its portfolio over the years, creating a valuable data resource with which researchers can rapidly validate clinical hypotheses and algorithms for clinical decision-making, and matched specimen collections, which are also advancing the development of prognostic variables, biomarkers, and therapeutics for diseases related to the mission of NIDDK. In 2022, NIDDK-CR relaunched its website, Resources for Research (R4R), featuring a streamlined approach to the request process and enhancements to support findability and accessibility of NIDDK resources.

Registered Biobank Name	NIDDK Central Repository
Biobank Leader	Kurt Langenbach PI
Country	United States
Email for biobank inquiries	kurt.langenbach@precisionformedicine.com
Principal Investigator	Rebecca M. Rodriguez Director, NIDDK Central Repository Program
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).